FDA-Approved Breast Cancer Treatments
FDA-APPROVED BREAST CANCER TREATMENTS
Generic Brand Strength Form Adult Dose
ALKYLATING AGENTS
cyclophos
phamide
25mg, 50mg tabs 1−5mg/kg/day.
500mg, 1g, 2g pwd for IV inj after reconstitution 40−50mg/kg in divided doses over 2−5 days or 10−15mg/kg every 7−10 days or 3−5mg/kg twice weekly.
thiotepa 15mg pwd for IV, intravesical, or intracavitary admin after reconstitution 0.3−0.4mg/kg IV once every 1−4wks.
ANTIBIOTICS (CYTOTOXIC)
doxorubicin 10mg, 20mg, 50mg pwd for IV inj after reconstitution Monotherapy: 60−75mg/m² every 21 days. Combination therapy: 40−60mg/m² every 21−28 days.
2mg/mL soln for IV inj
epirubicin Ellence 2mg/mL soln for IV infusion 100−120mg/m² on Day 1 or divided equally given on Days 1 and 8 of each cycle.
ANTIESTROGEN
tamoxifen 10mg, 20mg tabs Treatment: 20–40mg/day (give doses >20mg in the AM and PM). Reduction of incidence in high-risk women or DCIS: 20mg once daily for 5yrs.
Soltamox Oral 
Solution
10mg/
 
5mL
oral soln Metastatic: 20–40mg/day (give doses >20mg in the AM and PM). Adjuvant: 20mg daily for 5–10yrs. Reduction of incidence in high-risk women or DCIS: 20mg once daily for 5yrs.
toremifene Fareston 60mg tabs 60mg once daily.
ANTIMETABOLITES
capecitabine Xeloda 150mg, 500mg tabs Monotherapy: 1250mg/m² twice daily
Combination therapy: Give with docetaxel 75mg/m² IV infused over 1hr every 3wks.
fluorouracil 50mg/mL soln for IV inj 12mg/kg once daily for 4 successive days; max 800mg/day.
gemcitabine Gemzar 200mg, 1g pwd for IV infusion after reconstitution 1250mg/m² on Days 1 and 8 of each 21-day cycle; give with paclitaxel 175mg/m² administered on Day 1 before gemcitabine.
Infugem 1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL soln for IV infusion.
metho
trexate
25mg/mL soln for IV, IM, intra-arterial, or intrathecal admin after dilution See drug monograph and manufacturer’s full labeling.
1g pwd for IV, IM, intra-arterial, or intrathecal admin after dilution
Trexall 5mg, 7.5mg, 10mg, 15mg scored tabs
ANTIMICROTUBULE AGENTS
docetaxel Taxotere 40mg/mL soln for IV infusion after dilution 60−100mg/m² once every 3wks.
eribulin mesylate Halaven 0.5mg/mL soln for IV inj 1.4mg/m² IV inj over 2−5min on Days 1 and 8 of each 21‑day cycle.
ixabepilone Ixempra 15mg, 45mg pwd for IV infusion after constitution and dilution 40mg/m² once every 3wks.
paclitaxel Abraxane 100mg IV infusion; inj susp after reconstiution 260mg/m² every 3wks.
Taxol 6mg/mL soln for IV infusion after dilution 175mg/m² every 3wks.
vinblastine 10mg lyophilized pwd for IV inj or infusion after reconstitution 5.5−7.4mg/m² once weekly (see full labeling).
1mg/mL soln for IV inj or infusion
AROMATASE INHIBITOR
anastrozole Arimidex 1mg tabs 1mg once daily.
exemestane Aromasin 25mg tabs 25mg once daily.
letrozole Femara 2.5mg tabs 2.5mg once daily.
ESTROGEN
conjugated estrogens Premarin 0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg tabs 10mg 3 times daily for at least 3mos.
estradiol Estrace 0.5mg, 1mg, 2mg scored tabs 10mg 3 times daily for at least 3mos.
ESTROGEN RECEPTOR ANTAGONIST
fulvestrant Faslodex 50mg/mL soln for IM inj Give by slow IM inj (1–2mins). 500mg (as two 5mL inj, one in each buttock) on Days 1, 15, 29, then once monthly thereafter. Combination therapy: give with palbociclib 125mg daily with food for 21 days, followed by 7 days off, or with abemaciclib 150mg twice daily, or with ribociclib 600mg daily for 21 days followed by 7 days off; in pre/perimenopausal women: also treat with LHRH agonists.
GnRH ANALOGUE
goserelin Zoladex 3.6mg SC implant One 3.6mg implant every 28 days.
HER2-TARGETED ANTIBODY-DRUG CONJUGATE
ado-trastuzumab emtansine Kadcyla 100mg, 160mg lyophilized pwd for IV infusion after reconstitution and dilution Infuse over 90mins. 3.6mg/kg max every 3wks (21-day cycle). MBC: treat until disease progression or unacceptable toxicity. EBC: treat for a total of 14 cycles unless disease recurrence or unacceptable toxicity.
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2) INHIBITOR
pertuzumab Perjeta 420mg/
 
14mL (30mg/
 
mL)
soln for IV infusion Initially 840mg IV over 60mins, followed every 3wks thereafter by a dose of 420mg IV over 30–60mins, in combination with trastuzumab. MBC: also give with docetaxel. Neoadjuvant: give every 3wks for 3–6 cycles as part of one of the treatment regimens for EBC (see full labeling). Adjuvant: give every 3wks for 1yr (up to 18 cycles) or until disease recurrence or unacceptable toxicity, whichever occurs first, as part of EBC regimen (see full labeling).
trastuzumab Herceptin 440mg lyophilized pwd for IV infusion after reconstitution and dilution Initially 4mg/kg over 90mins, followed by 2mg/kg over 30mins weekly; administer until tumor progression. Adjuvant treatment, combination therapy: see full labeling.
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2) INHIBITOR + ENDOGLYCOSIDASE
trastuzumab + hyaluronidase-oysk Herceptin Hylecta 600mg/5mL + 10,000units/5mL soln for SC inj 600mg/10,000 Units SC over 2–5mins once every 3wks. Adjuvant treatment: treat for 52wks or until disease recurrence, whichever occurs first; extending treatment beyond 1yr: not recommended. Metastatic treatment: treat until disease progression.
KINASE INHIBITOR
abemaciclib Verzenio 50mg, 100mg, 150mg, 200mg tabs Combination: 150mg twice daily with fulvestrant or an aromatase inhibitor (see full labeling); in pre/perimenopausal women (in combination with fulvestrant): also treat with a gonadotropin-releasing hormone agonist. Monotherapy: 200mg twice daily. Both: continue until disease progression or unacceptable toxicity.
lapatinib Tykerb 250mg tabs HER2-positive (metastatic): 1250mg once daily on Days 1–21 continuously in combination with capecitabine 2000mg/m2/day on Days 1–14 in a repeating 21 day cycle; continue until disease progression or unacceptable toxicity. HR-positive, HER2-positive (metastatic): 1500mg once daily continuously in combination with letrozole 2.5mg once daily.
palbociclib Ibrance 75mg, 100mg, 125mg caps 125mg once daily for 21 days followed by 7 days off to complete a 28-day cycle, in combination with an aromatase inhibitor or with fulvestrant 500mg on Days 1, 15, 29, and once monthly thereafter. In the combination with fulvestrant therapy: pre/perimenopausal women should be treated with LHRH agonists. In the combination with aromatase inhibitor therapy for men: consider LHRH agonist.
ribociclib Kisqali 200mg tabs 600mg once daily for 21 days followed by 7 days off to complete 28-day cycle. In combination with an aromatase inhibitor: see drug’s full labeling. In combination with fulvestrant: give fulvestrant 500mg on Days 1, 15, 29, then once monthly thereafter. Pre/perimenopausal women on combination therapy: also treat with LHRH agonist.
ribociclib + letrozole Kisqali Femara Co-Pack 200mg + 2.5mg tabs Kisqali: 600mg once daily for 21 days, followed by 7 days off to complete 28-day cycle. Femara: 2.5mg once daily throughout the 28-day cycle. Pre/perimenopausal women: also treat with LHRH agonist.
mTOR KINASE INHIBITOR
everolimus Afinitor 2.5mg, 5mg, 7.5mg, 10mg tabs 10mg once daily until disease progression or unacceptable toxicity.
PD-L1 BLOCKING ANTIBODY
atezolizumab Tecentriq 60mg/mL soln for IV infusion after dilution 840mg on Days 1 and 15, followed by paclitaxel protein-bound 100mg/m2 on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR
alpelisib Piqray 50mg, 150mg, 200mg tabs 300mg once daily with food (in combination with fulvestrant 500mg on Days 1, 15, and 29, then once monthly thereafter) until disease progression or unacceptable toxicity.
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR
olaparib Lynparza Tablets 100mg, 150mg tabs 300mg twice daily until disease progression or unacceptable toxicity; max 600mg daily.
talazoparib Talzenna 0.25mg, 1mg caps 1mg once daily until disease progression or unacceptable toxicity.
PROGESTIN
megestrol acetate 20mg, 40mg scored tabs 40mg 4 times daily.
SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)
raloxifene Evista 60mg tabs 60mg once daily.
NOTES

Key: DCIS = ductal carcinoma in situ; EBC = early breast cancer; MBC = metastatic breast cancer
Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 7/2019)

This article originally appeared on MPR